Reportlinker

http://www.reportlinker.com/

Reportlinker Adds Gastrointestinal Pharmaceuticals: Technologies and Markets

Tuesday 3rd of November 2009 10:58

NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

Gastrointestinal Pharmaceuticals: Technologies and Markets

http://www.reportlinker.com/p0157462/Gastrointestinal-Pharmaceuticals-Technologies-and-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

Overall sales in the gastrointestinal disorder treatment market amounted to $34.2 billion in 2007, and decreased slightly to $31.1 billion in 2009. By 2014, they are projected to reach $32.2 billion, for a 5-year compound annual growth rate (CAGR) of 0.7%.

The largest segment of the market, prescription gastrointestinal drugs, was valued at $27.4 billion in 2008; this is expected to decrease to $26,3 billion in 2009, and to reach $27 billion in 2014, for a 5-year CAGR of 0.5%.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 1

SCOPE OF REPORT 2

METHODOLOGY AND INFORMATION SOURCES 2

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 4

DISCLAIMER 4

Chapter-2: EXECUTIVE SUMMARY

EXECUTIVE SUMMARY 5

SUMMARY TABLE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, THROUGH 2014 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, 2007-2014 ($ MILLIONS) 6

Chapter-3: INDUSTRY OVERVIEW

STRUCTURE AND FUNCTION OF THE GASTROINTESTINAL SYSTEM 7

STRUCTURE AND FUNCTION (CONTINUED) 8

INGESTION AND PROPULSION OF FOOD 9

Mouth 9

Pharynx 9

Esophagus 10

DIGESTION AND ABSORPTION 10

Mouth 10

Stomach 10

Small Intestines 11

Physiology of Digestion 11

Physiology of Digestion (Continued) 12

ELIMINATION 13

Large Intestine 13

LIVER, BILIARY TRACT AND PANCREAS 14

LIVER 14

BILIARY TRACT 14

Bilirubin Metabolism 15

PANCREAS 15

GASTROINTESTINAL TRACT DISORDERS 15

DYSPHAGIA 15

Dysphagia (Continued) 16

ESOPHAGEAL AND ABDOMINAL PAIN 17

VOMITING 18

INTESTINAL GAS 18

CONSTIPATION 19

DIARRHEA 19

TABLE 1 CAUSES OF DIARRHEA 20

GASTROINTESTINAL TRACT WALL DISORDERS 21

GASTRITIS 21

TABLE 2 COMMON CAUSES OF GASTRITIS 21

GASTROENTERITIS 22

PEPTIC ULCER DISEASE 23

Peptic Ulcer Disease (Continued) 24

GASTRIC ULCERS 25

DUODENAL ULCERS 26

INFLAMMATORY BOWEL DISEASE 27

ULCERATIVE COLITIS 28

CROHN'S DISEASE 28

ENTEROCOLITIS 29

DIVERTICULAR DISEASE 30

GASTROINTESTINAL TRACT MOTILITY DISORDERS 30

IRRITABLE BOWEL SYNDROME 30

INTESTINAL OBSTRUCTION 31

GASTROINTESTINAL MALABSORPTION DISORDERS 32

CELIAC DISEASE 32

TROPICAL SPRUE 33

CANCERS OF THE GASTROINTESTINAL TRACT 33

ESOPHAGEAL CANCER 33

GASTRIC CANCER 34

LIVER CANCER 35

PANCREATIC CANCER 36

SMALL INTESTINAL CANCER 37

COLONIC POLYPS AND COLON CANCER 37

Colonic Polyps and (Continued) 38

U.S. DEMOGRAPHICS 39

TABLE 3 U.S. ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GASTROINTESTINAL CONDITIONS 39

TABLE 4 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS) 40

FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS) 40

FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2009 AND 2014 (%) 41

PILL-SIZED VIDEO CAMERA 42

PILLCAM ESO 42

SMARTPILL 42

RADIO FREQUENCY IDENTIFICATION TECHNOLOGY 43

IPHONE APPLICATION 43

ENTERIC NERVOUS SYSTEM 43

INSURANCE COVERAGE 44

MONOCLONAL ANTIBODIES 45

WYETH IN SUIT WITH STATES 46

GENERIC INFLUENCE 46

BRANDED VS OTC PROTON PUMP INHIBITORS 47

MAIL ORDER TRENDS 48

MAIL ORDER TRENDS (CONTINUED) 49

Chapter-4: PRESCRIPTION PRODUCT SEGMENTS BY TYPE

ANTIDIARRHEALS 50

SYSTEMICALLY ACTING ANTIDIARRHEALS 51

OPIUM PRODUCTS 51

TABLE 5 MARKETED ANTIDIARRHEAL PRODUCTS 52

MARKET SIZE AND GROWTH 52

TABLE 6 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS) 53

FIGURE 3 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS) 53

COMPETITIVE STRUCTURE AND MARKET SHARE 54

TABLE 7 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES AND MARKET SHARE LEVELS, BY MANUFACTURER, 2009 ($ MILLIONS/%) 54

FIGURE 4 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES, 2009 ($ MILLIONS) 55

ANTIEMETICS 55

LOCALLY ACTING ANTIEMETICS 55

CENTRALLY ACTING ANTIEMETICS 56

ANTIDOPAMINERGICS 56

Antidopaminergics (Continued) 57

ANTICHOLINERGICS 58

MISCELLANEOUS ANTIEMETICS 58

Miscellaneous Antiemetics (Continued) 59

Miscellaneous Antiemetics (Continued) 59

TABLE 8 MARKETED ANTIEMETIC PRODUCTS 60

TABLE 8 (CONTINUED) 61

MARKET SIZE AND GROWTH 61

TABLE 9 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 61

FIGURE 5 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, 2007-2014 ($ MILLIONS) 62

COMPETITIVE STRUCTURE AND MARKET SHARE 62

TABLE 10 GLOBAL PRESCRIPTION ANTIEMETIC REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 63

FIGURE 6 GLOBAL PRESCRIPTION ANTIEMETICS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS) 63

GASTROINTESTINAL CANCER TREATMENTS 63

GASTROINTESTINAL CANCER (CONTINUED) 64

GASTROINTESTINAL CANCER (CONTINUED) 65

TABLE 11 MARKETED GASTROINTESTINAL CANCER PRODUCTS 66

MARKET SIZE AND GROWTH 66

TABLE 12 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 66

FIGURE 7 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, 2007-2014 ($ MILLIONS) 67

COMPETITIVE STRUCTURE AND MARKET SHARE 67

TABLE 13 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%) 68

FIGURE 8 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES, 2009 ($ MILLIONS) 68

H2 INHIBITORS 68

H2 INHIBITORS (CONTINUED) 69

H2 INHIBITORS (CONTINUED) 70

H2 INHIBITORS (CONTINUED) 71

TABLE 14 MARKETED H2 INHIBITORS PRODUCTS 72

MARKET SIZE AND GROWTH 72

TABLE 15 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 73

FIGURE 9 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS) 73

COMPETITIVE STRUCTURE AND MARKET SHARE 73

TABLE 16 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%) 74

FIGURE 10 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES, 2009 ($ MILLIONS) 74

LAXATIVES 74

LAXATIVES (CONTINUED) 75

TABLE 17 MARKETED LAXATIVE PRODUCTS 76

MARKET SIZE AND GROWTH 77

TABLE 18 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 77

FIGURE 11 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS) 78

COMPETITIVE STRUCTURE AND MARKET SHARE 78

TABLE 19 GLOBAL PRESCRIPTION LAXATIVE REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%) 78

FIGURE 12 GLOBAL PRESCRIPTION LAXATIVE REVENUES, 2009 ($ MILLIONS) 79

PROTON PUMP INHIBITORS 79

PROTON PUMP INHIBITORS (CONTINUED) 80

PROTON PUMP INHIBITORS (CONTINUED) 81

TABLE 20 MARKETED PROTON PUMP INHIBITOR PRODUCTS 82

MARKET SIZE AND GROWTH 82

TABLE 21 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 82

FIGURE 13 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS) 83

COMPETITIVE STRUCTURE AND MARKET SHARE 83

TABLE 22 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 84

FIGURE 14 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES BY MANUFACTURER, 2009 ($ MILLIONS) 84

BOWEL ANTI-INFLAMMATORY 84

BOWEL ANTI-INFLAMMATORY (CONTINUED) 85

BOWEL ANTI-INFLAMMATORY (CONTINUED) 86

TABLE 23 MARKETED BOWEL ANTI-INFLAMMATORY PRODUCTS 87

MARKET SIZE AND GROWTH 87

TABLE 24 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 87

FIGURE 15 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, 2007-2014 ($ MILLIONS) 88

COMPETITIVE STRUCTURE AND MARKET SHARE 88

TABLE 25 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%) 89

FIGURE 16 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES BY MANUFACTURER, 2009 ($ MILLIONS) 89

OTHER GASTROINTESTINAL PRODUCTS 89

ANTISPASMODICS 90

TABLE 26 MARKETED ANTISPASMODIC PRODUCTS 90

DIGESTANTS 90

GASTRIC ACIDIFIERS 91

PANCREATIC ENZYMES 91

TABLE 27 MARKETED DIGESTANT PRODUCTS 92

EVACUANTS 92

TABLE 28 MARKETED EVACUANTS PRODUCTS 92

MUCOSAL PROTECTANTS 93

TABLE 29 MARKETED MUCOSAL PROTECTANT PRODUCTS 93

PROSTAGLANDINS 93

TABLE 30 MARKETED PROSTAGLANDIN PRODUCTS 94

STIMULANTS 94

TABLE 31 MARKETED STIMULANT PRODUCTS 94

MARKET SIZE AND GROWTH 95

TABLE 32 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 95

FIGURE 17 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, 2007-2014 ($ MILLIONS) 95

COMPETITIVE STRUCTURE 96

TOTAL GLOBAL PRESCRIPTION GASTROINTESTINAL MARKET SIZE AND GROWTH 96

TABLE 33 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, THROUGH 2014 ($ MILLIONS) 96

FIGURE 18 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, 2007-2014 ($ MILLIONS) 97

TOTAL U.S. PRESCRIPTION GASTROINTESTINAL COMPETITIVE ANALYSIS 97

TABLE 34 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, (ESTIMATED 2009) 98

FIGURE 19 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, 2009 ESTIMATED (%) 99

Chapter-5: OTC PRODUCT SEGMENTS BY TYPE

ANTACIDS 100

SYSTEMIC ANTACIDS 101

Sodium Bicarbonate 101

NONSYSTEMIC ANTACIDS 101

Calcium Carbonate 101

Aluminum Products 102

Magnesium Products 102

Combination Products 103

TABLE 35 MARKETED OTC ANTACID PRODUCTS 103

TABLE 35 (CONTINUED) 104

MARKET SIZE AND GROWTH 104

TABLE 36 GLOBAL OTC ANTACID MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 104

FIGURE 20 GLOBAL OTC ANTACID MARKET BY REGION, 2007-2014 ($ MILLIONS) 105

COMPETITIVE STRUCTURE AND MARKET SHARE 105

TABLE 37 GLOBAL OTC ANTACID REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 106

FIGURE 21 GLOBAL OTC ANTACID MARKET SHARE BY MANUFACTURER, 2009 (%) 106

LOCALLY ACTING ANTIDIARRHEALS 106

ADSORBENTS 107

INTESTINAL FLORA MODIFIERS 108

TABLE 38 MARKETED OTC ANTIDIARRHEAL PRODUCTS 108

MARKET SIZE AND GROWTH 108

TABLE 39 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 109

FIGURE 22 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, 2007-2014 ($ MILLIONS) 109

COMPETITIVE STRUCTURE AND MARKET SHARE 110

TABLE 40 GLOBAL OTC ANTIDIARRHEALS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS/%) 110

FIGURE 23 GLOBAL OTC ANTIDIARRHEALS MARKET SHARE BY MANUFACTURER, 2009 (%) 110

H2 INHIBITORS 111

H2 INHIBITORS (CONTINUED) 112

H2 INHIBITORS (CONTINUED) 113

TABLE 41 MARKETED OTC H2 INHIBITORS PRODUCTS 114

MARKET SIZE AND GROWTH 114

TABLE 42 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 114

FIGURE 24 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS) 115

COMPETITIVE STRUCTURE AND MARKET SHARE 115

TABLE 43 GLOBAL OTC H2 INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 116

FIGURE 25 GLOBAL OTC H2 INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%) 116

PROTON PUMP INHIBITORS 116

OMEPRAZOLE (PRILOSEC, PROCTER & GAMBLE) 116

TABLE 44 MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS 117

MARKET SIZE AND GROWTH 117

TABLE 45 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 118

FIGURE 26 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS) 118

COMPETITIVE STRUCTURE AND MARKET SHARE 119

TABLE 46 GLOBAL OTC PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 119

FIGURE 27 GLOBAL OTC PROTON PUMP INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%) 119

LAXATIVES 120

TABLE 47 MARKETED OTC LAXATIVE PRODUCTS 120

TABLE 47 (CONTINUED) 121

MARKET SIZE AND GROWTH 121

TABLE 48 GLOBAL OTC LAXATIVES MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 121

FIGURE 28 GLOBAL OTC LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS) 122

COMPETITIVE STRUCTURE AND MARKET SHARE 122

TABLE 49 GLOBAL OTC LAXATIVE REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 122

FIGURE 29 GLOBAL OTC LAXATIVE MARKET SHARE BY MANUFACTURER, 2009 (%) 123

TOTAL OTC GASTROINTESTINAL DRUG MARKET SIZE AND GROWTH 123

TABLE 50 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, THROUGH 2014 ($ MILLIONS) 123

FIGURE 30 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, 2007-2014 ($ MILLIONS) 124

TOTAL OTC GASTROINTESTINAL DRUG COMPETITIVE ANALYSIS 124

TABLE 51 TOTAL MANUFACTURERS' REVENUES AND MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 ($ MILLIONS/%) 125

FIGURE 31 TOTAL MANUFACTURERS' MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 (%) 125

RESEARCH AND DEVELOPMENT 125

METOSOLV ODT 126

NEXIUM LOW-DOSE ASPIRIN COMBINATION 126

REZONIC 126

SANVAR 126

TAK-390MR (KAPIDEX) 126

ZENPEP 127

AB-1001 127

ALICAFORSEN 127

APF 530 128

CROFELEMER 128

HUMIRA 128

LINACLOTIDE 128

METHYLNALTREXONE (MNTX) (RELSTAR) 128

MLN 0002 (VEDOLIZUMAB) 129

ORBEC 129

PROCHYMAL 129

RENZAPRIDE 129

REMICADE 130

REZULAR 130

RIFAXIMAN (XIFAXAN) 130

SUTENT 130

ALICAFORSEN ENEMA 130

DEXTOFISOPAM 131

EKB-569 131

GTI-2040 131

PUMOSETRAG 131

RDP-58 132

SORAPRAZAN 132

TALNETANT 132

BL-1030 132

BL-1050 132

TABLE 52 GASTROINTESTINAL DISORDER TREATMENTS IN DEVELOPMENT 133

TABLE 52 (CONTINUED) 134

TABLE 52 (CONTINUED) 135

TABLE 52 (CONTINUED) 136

TABLE 52 (CONTINUED) 137

TABLE 52 (CONTINUED) 138

TABLE 52 (CONTINUED) 139

TOTAL MARKET ANALYSIS 139

TABLE 53 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER MARKET BY CATEGORY, THROUGH 2014 ($ MILLIONS) 139

FIGURE 32 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY CATEGORY, 2007-2014 ($ MILLIONS) 140

Chapter-6: INDUSTRY PARTICIPANTS BY PRODUCT TYPE

TABLE 54 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS' REVENUES AND MARKET SHARE BY TYPE, 2009 ($ MILLIONS/%) 141

FIGURE 33 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS' MARKET SHARE BY TYPE, 2009 (%) 142

COMPANY PROFILES 142

ASTRAZENECA 142

History 143

AXCAN PHARMA, INC. 143

History 144

CENTOCOR, INC. 145

History 146

EISAI, INC. 146

History 147

GENENTECH, INC. 147

History 148

GLAXOSMITHKLINE 148

Glaxosmithkline (Continued) 149

Glaxosmithkline (Continued) 150

History 151

JOHNSON & JOHNSON 151

History 151

MCNEIL CONSUMER HEALTHCARE 152

History 152

MERCK & CO., INC. 152

History 153

NOVARTIS INTERNATIONAL AG 153

History 154

PFIZER, INC. 154

History 155

PROCTER & GAMBLE CO. 155

History 156

ROCHE 156

History 157

SANOFI-AVENTIS 157

History 157

SALIX PHARMACEUTICALS, LTD. 158

History 158

SOLVAY PHARMACEUTICALS 159

History 159

TAKEDA PHARMACEUTICALS NORTH AMERICA 160

History 160

WYETH 161

History 162

Chapter-7: CONTACT INFORMATION FOR GASTROINTESTINAL MARKET PARTICIPANTS

3M CORP. 163

ABBOTT LABORATORIES 163

ABEILLE PHARMA, INC. 163

ACAMBIS, PLC 163

ACE BIOSCIENCES A/S 163

AGI THERAPEUTICS, INC. 163

ALCHEMIA, LTD. 164

ALIZYME, PLC 164

ALLERGAN, INC. 164

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. 164

ALTANA PHARMA AG 164

ALVINE PHARMACEUTICALS, INC. 164

AMARIN CORP. 164

AMGEN, INC. 165

ANTIGENICS, INC. 165

APOTHECON B.V. 165

AP PHARMA, INC. 165

ARCO PHARMACEUTICALS 165

ASPHELIA PHARMACEUTICALS, INC. 165

ARYX THERAPEUTICS, INC 165

ASTELLAS PHARMA, INC. 166

ASTRAZENECA, PLC 166

AXCAN PHARMA, INC. 166

BERTEK (MYLAN LABORATORIES INC.) 166

BIOBALANCE, INC. 166

BIOGEN IDEC, INC. 166

BIOLINERX, LTD. 167

BRAINTREE LABORATORIES, INC. 167

BRISTOL-MYERS SQUIBB CO. 167

CELLDEX THERAPEUTICS, INC. 167

CENTOCOR ORTHO BIOTECH, INC. 167

CEPHALON, INC. 167

CERIMON PHARMA, INC. 167

CHEMOCENTRYX, INC. 168

CLAVIS PHARMA ASA 168

COSMO PHARMACEUTICALS SPA 168

CYTOKINE PHARMASCIENCES, INC. 168

DEBIOPHARM S.A. 168

DOR BIOPHARMA, INC. 168

EISAI CO., LTD. 169

ELAN CORPORATION, PLC 169

EMD SERONO, INC. 169

ENZO 169

EURAND PHARMACEUTICALS, INC. 169

EVOKE PHARMA 169

FRESENIUS KABI AG 169

GENENTECH, INC. 170

GENZYME GENERAL 170

GLAXOSMITHKLINE, PLC 170

GLAXOSMITHKLINE CONSUMER HEALTHCARE 170

GLENMARK PHARMACEUTICALS, LTD. 170

H3 PHARMA, INC. 170

HELSINN HEALTHCARE 171

HOFFMAN-LAROCHE, LTD. (ROCHE) 171

HYPERION THERAPEUTICS, INC. 171

IMMUCELL CORP. 171

ISIS PHARMACEUTICALS. INC. 171

JANSSEN PHARMACEUTICA PRODUCTS, LP (JOHNSON & JOHNSON) 171

JOHNSON & JOHNSON 171

LORUS THERAPEUTICS, INC. 172

MCNEIL CONSUMER & SPECIALTY PHARMACEUTICALS 172

MEDISCA, INC. 172

MERCK & CO., INC. 172

MONARCH LABS 172

NABI BIOPHARMACEUTICALS 172

NOVARTIS CORP. 172

NPS PHARMACEUTICALS, INC. 173

OTSUKA AMERICA PHARMACEUTICAL, INC. 173

PFIZER, INC. 173

THE PROCTER & GAMBLE CO. 173

PRODIGENE, INC. 173

PROGENICS PHARMACEUTICALS, INC. 173

RAVEN BIOTECHNOLOGIES, INC. 173

RELIANT PHARMACEUTICALS, INC. 174

ROXANE LABORATORIES, INC. 174

SALIX PHARMACEUTICALS, LTD. 174

SANOFI-AVENTIS 174

SANTARUS, INC. 174

SCHERING AG 174

SCHWARZ PHARMA AG 174

SERONO S.A. 175

SHIRE PHARMACEUTICALS GROUP, PLC 175

SOLVAY S.A. 175

SUCAMPO PHARMACEUTICALS, INC. 175

SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC) 175

TAKEDA PHARMACEUTICAL NORTH AMERICA 175

TARGACEPT, INC. 176

THERAVANCE, INC. 176

UCB PHARMA, INC. 176

UNIMED PHARMACEUTICALS, INC. 176

PHARMOS PHARMACEUTICALS, INC. 176

WATSON PHARMACEUTICALS, INC. 176

WYETH (WHITEHALL-ROBINS HEALTHCARE, INC.) 176

To order this report:

Gastrointestinal Pharmaceuticals: Technologies and Markets

http://www.reportlinker.com/p0157462/Gastrointestinal-Pharmaceuticals-Technologies-and-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker

Source PR Newswire


www.prnewswire.co.uk

Browse news from 2009

Download PDF